Global Biotech Innovators Lead the Charge in the Fight Against Coronavirus

In these unprecedented times, global biotechnology companies, both large and small, are coming together to work on vaccines, therapeutics and diagnostics to eradicate COVID-19. Global collaborations and the decades-long investments in new technology, research and treatments have enabled an unprecedented response to the development of vaccines, treatments, and diagnostics for COVID-19.  

Representing biotechnology innovators globally, we believe that combatting this pandemic calls for a global, coordinated, transparent, robust, large-scale and science-based response.  

Our aim is to:  

• Support our small to large biotechnology companmembers that are researching and developing new vaccines, diagnostics, and treatments for use in the fight against COVID-19;

• Ensure the efficient and safe supply of medicines to the patients that need them; and

• Create a bridge to global governments, institutions, and funding opportunities for COVID-19 research.

See here for more information on the global biotechnology sector’s commitments on COVID-19. 

ICBA Resources

Global CollaborationsThe global biotechnology sector is committed to working collaboratively across the research and healthcare communities, leading with science and leveraging our resources to tackle this outbreak. See here for more information on global collaborations working to address the current pandemic. 

Policy Issues: Policies that support biotechnology innovation across the globe are necessary to successfully fight COVID-19. See here for more on policies affecting COVID-19 R&D.

COVID-19 Resources By ICBA Association: National biotech sectors around the world are ramping up R&D efforts. See here for more information from ICBA members on national COVID-19 efforts.

Advancing COVID-19 Treatments, Vaccines and Diagnostics 

Industry analysis by the Biotechnology Innovation Organization (BIO) has been used to create a interactive view of the COVID-19 pipeline. The data shows that nearly three-quarters of the hundreds of R&D programs in the pipeline are from small companies.

 

Contact Us 

For further information on the global biotechnology sector’s contribution to the COVID-19 response, please email us.